

The UCLA Heart Failure, Mechanical Support and
Heart Transplant Team presents

UCLA Heart Failure Symposium 2025 State-of-the-Art Updates & Therapies for Advanced Heart Failure

A Hybrid CME Conference

*Available as both a live in-person
and live virtual activity*

Saturday, September 20, 2025

Marina del Rey Marriott

4100 Admiralty Way

Marina del Rey, CA

UCLA Heart Failure Symposium 2025

Course Description

Heart failure affects approximately six million Americans and is the most common diagnosis for acute hospitalization in patients over 65 years. Over the next decade, we will see a dramatic increase in the number of patients in the community with advanced heart failure who can benefit from advanced therapies for complex cardiac disease. Academic medical centers, such as UCLA, have an opportunity to integrate treatment advances into a comprehensive patient-centered heart failure management program. UCLA Health wants to enhance the role of the primary care physician and primary cardiologist as the central provider for continuity of care for these complex heart failure patients.

The 13th Annual UCLA Heart Failure Symposium 2025 will:

1. Discuss general heart failure treatment options including short and long term mechanical circulatory support therapy, heart transplantation, pulmonary hypertension management, high risk percutaneous and structural interventions, and complex congenital heart disease management.
2. Emphasize the need for developing networks linking academic centers with community physicians to manage these patients through the evolution of their disease pre and post advanced cardiac intervention.
3. Discuss heart failure therapies in cardio-oncology, amyloidosis and new medication updates, as well as address patient and care-provider's specific needs and perspectives.

Target Audience

Family practitioners, internists, cardiologists, pediatricians, nurses and all other healthcare professionals taking care of heart failure patients, as well as the interested lay public.

Learning Objectives

At the conclusion of the program participants will be able to:

- Identify the epidemiology and pathophysiology of heart failure and the need for mechanical circulatory support with a growing heart failure population.
- Identify indications for and management of lifelong left ventricular assist device therapy.
- Implement shared care programs with the community and co-manage patients in need of complex cardiac therapies including LVAD therapy, heart transplantation, pulmonary hypertension management, high risk percutaneous interventions, and complex congenital heart disease management.
- Discuss the comprehensive multidisciplinary care and services available to complex cardiac patients within the UCLA Heart Failure Program.

General Information

Saturday, September 20, 2025

7:00 am – 4:00 pm

Conference Location:

**Marina del Rey Marriott
(California Ballroom)**
4100 Admiralty Way
Marina del Rey, CA

Parking:

Valet parking \$25

In-person attendees will be provided breakfast, lunch, and reception at the meeting site.

The **UCLA Heart Failure Symposium 2025** will also be available through a live virtual meeting web platform.

- Attendees who choose to attend the live virtual activity will receive a virtual meeting link and password to access the live virtual conference.
- All registrants (live or virtual) will be provided the opportunity to review recorded sessions up to 3 weeks following the conference.
- The recorded sessions are not certified for CME credit.

Officially endorsed by the Heart Failure Society of America. The opinions presented in this educational activity do not necessarily reflect the opinions or recommendations of the HFSA.

Program Schedule

| | | |
|--|--|---|
| 7:45 | Welcome | Ali Nsaïr, MD |
| Session I: What's New in 2025 – Breakthroughs in Advanced Heart Failure | | |
| 8:00 | State-of-the-Art Medical Therapies in Advanced Heart Failure: What is New in 2025 | Gregg Fonarow, MD, FACC |
| 8:20 | A New Era of Organ Preservation and Procurement in Heart Transplantation: Going the Distance | Abbas Ardehali, MD, FACS |
| 8:40 | Robotic Surgical Interventions: Minimally Invasive Mitral Surgery | Richard Shemin, MD |
| 9:00 | Aortic Stenosis in Heart Failure Patients: When to Consider TAVR | Olcaý Aksoy, MD |
| 9:20 | Cardiogenic Shock: From Mobile ECMO to ECPEL-LAS | Peyman Benharash, MD |
| 9:40 | Panel Discussion | |
| 10:00 | Break | |
| Session II: Nuts and Bolts: Everyday Prevention and Management of Heart Failure | | |
| 10:20 | Afib Ablation in Heart Failure – King of the Castle | Peter Hanna, MD, PhD |
| 10:40 | Time to Relax: Novel Therapies for Hypertrophic Cardiomyopathy | Arnold S. Baas, MD, FACC, FACP |
| 11:00 | Cardiac Amyloidosis: A New Era of Diagnostics and Therapeutics | Darko Vucicevic, MD |
| 11:20 | Releasing the Brakes on the Immune system in Cancer: Implications on Myocarditis and Beyond | Eric Yang, MD |
| 11:40 | Advances In Heart Failure Therapies, Beyond 2025 | Ali Nsaïr, MD |
| 12:00 | Panel Discussion | |
| 12:20 | Lunch | |
| Session III: Going the Distance: A Multidisciplinary approach to Advanced HF | | |
| 1:20 | When to Refer: A Tale of Two Patients | Daniel Cruz, MD, PhD |
| 1:50 | Powering The Heart: Unlocking the Potential of Home Inotrope Therapy | UCLA Cardiomyopathy Advance Practice Nurses and Christine Bui, MD |
| 2:20 | Cardioobstetrics: Maternal Health in Cardiomyopathy Patients | Megan Kamath, MD |
| 2:40 | Pharmacologic Options for Managing Obesity in Patients with Heart Failure | Vijay Surampudi, MD, MS |
| 3:00 | Pulmonary Hypertension Management: From Surgical to Medical Therapies | Rajan Saggar, MD |
| 3:10 | Panel Discussion | |
| 3:30 | Adjourn and Reception | |

David Geffen School of Medicine at UCLA

COURSE CHAIR

Ali Nsair, MD

Medical Director, Heart Transplantation and Mechanical Circulatory Support Device Services
Heart Failure
Interventional Cardiology
Broad Stem Cell Research Center

UCLA COURSE FACULTY AND PANEL PARTICIPANTS

Sabina Aleksandrovskaia, MSN, AGACNP-BC

Advanced Practice Nurse, Ahmanson-UCLA
Cardiomyopathy Center

Olcay Aksoy, MD, FACC

Assistant Clinical Professor
Interventional Cardiology
UCLA Cardiovascular Medicine

Abbas Ardehali, MD, FACS

Professor of Surgery and Medicine
Division of Cardiothoracic Surgery
William E. Connor Chair in Cardiothoracic Transplantation
Director, UCLA Heart, Lung, and Heart-Lung Transplant
Programs

Arnold S. Baas, MD, FACC, FACP

Professor of Medicine
Ahmanson-UCLA Cardiomyopathy Center
Mechanical Circulatory Support and Heart Transplantation
Program

Peyman Benharash, MD, PhD

Assistant Professor in Residence
UCLA Cardiothoracic Surgery

Christine Bui, MD

Assistant Clinical Professor of Medicine
Cardiac Palliative Care Program
Department of Internal Medicine, UCLA

Julie W. Creaser, RN, MN, CNS, CHFN

Advanced Practice Nurse, Ahmanson-UCLA
Cardiomyopathy Center

Daniel Cruz, MD, PhD

Associate Clinical Professor of Medicine
Associate Director, Heart Transplant
Ahmanson-UCLA Cardiomyopathy Center
Mechanical Circulatory Support and Heart Transplantation
Program

Gregg C. Fonarow, MD, FACC, FAHA, HFSA

Chief, UCLA Division of Cardiology
Director, Ahmanson-UCLA Cardiomyopathy Center
Co-Director, UCLA Preventative Cardiology Program
The Eliot Corday Chair in Cardiovascular Medicine and
Science

Peter Hanna, MD, PhD

Assistant Professor of Medicine
UCLA Cardiac Arrhythmia Center
David Geffen School of Medicine at UCLA

Megan Kamath, MD

Assistant Clinical Professor of Medicine
Ahmanson-UCLA Cardiomyopathy Center
Mechanical Circulatory Support and Heart Transplantation
Program

Nancy Livingston, MSN, NP-C

Advanced Practice Nurse
Ahmanson-UCLA Cardiomyopathy Center

Alexandra Monin, MSN, AGACNP-BC

Advanced Practice Nurse, Ahmanson-UCLA
Cardiomyopathy Center

Anca Rahman, RN, MSN, NP-C

Advanced Practice Nurse, Ahmanson-UCLA
Cardiomyopathy Center

Rajan Saggarr, MD

Associate Professor of Medicine
Director, Medical Intensive Care Unit
Lung and Heart-Lung Transplant and Pulmonary
Hypertension Programs

Richard J. Shemin, MD, FACC

Robert and Kelly Day Professor and Chief Cardiothoracic
Surgery
UCLA Executive Vice Chairman of Surgery
Co-Director of the Cardiovascular Center

Vijaya Surampudi, MD, MS

Associate Professor of Medicine
Clinical Chief of Clinical Nutrition
Department of Medicine

Elizabeth Vandenbogaart, MSN, ACNP-BC

Advanced Practice Nurse
Ahmanson-UCLA Cardiomyopathy Center

Darko Vucicevic, MD

Ahmanson-UCLA Cardiomyopathy Center
Mechanical Circulatory Support and Heart Transplantation
Program

Eric H. Yang, MD, FACC, FASE

Associate Clinical Professor of Medicine
Director, UCLA Cardio-Oncology Program
Associate Program Director, UCLA/Olive View/West LA VA
Cardiovascular Diseases Fellowship



UCLA Heart Failure Symposium 2025
Saturday, September 20, 2025

In-Person & Virtual Registration Fees

Live Virtual Conference: \$100

Live In-Person Conference: \$125



In-person registration includes access to the course materials, breakfast, patio lunch and reception at the meeting site. **Virtual registration** includes access to the live stream virtual conference. All registrants (live or virtual) will receive access to the conference recordings up to 3 weeks following the program.

To register using a credit card or ACH/electronic transfer, please visit <https://ucla.cloud-cme.com/HF2025> and click on **UCLA Heart Failure Symposium**.

*Credit card and check payments via phone, fax, or mail are no longer accepted.

Refunds

Due to the low enrollment fee, no refunds will be given for this conference.

Questions

If you have questions about enrollment, please call (310) 794-2620 or email: ccpd@mednet.ucla.edu.

Accreditation Statement

The David Geffen School of Medicine at UCLA is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The David Geffen School of Medicine at UCLA, designates this live activity for a maximum of 6.25 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The California State Board of Registered Nursing accepts courses approved for the *AMA PRA Category 1 Credits™* as meeting the continuing education requirements for license renewal. Nurses from states other than California should inquire with their local State Board for specific continuing education policies.

Disclosure Statement

The FDA has issued a concept paper that classifies commercial support of scientific and educational programs as promotional unless it can be affirmed that the program is “truly independent” and free of commercial influence. In addition to independence, the FDA requires that non-promotional, commercially supported education be objective, balanced and scientifically rigorous. The policy further states that all potential conflicts of interest of the CME staff and faculty be fully disclosed to the program’s participants. In addition, Accreditation Council for Continuing Medical Education policy mandates that the provider adequately manage all identified potential conflicts of interest prior to the program. UCLA fully endorses the letter and spirit of these concepts.

Center for Continuing Professional Development
UCLA David Geffen School of Medicine
BOX 956938, 885 Tiverton Drive, Suite 300
Los Angeles, CA 90095-6938

The UCLA Heart Failure, Mechanical Support
and Heart Transplant Team presents

UCLA Heart Failure Symposium 2025

State-of-the-Art Updates & Therapies
for Advanced Heart Failure

A Hybrid CME Conference

*Available as both a live in-person and
live virtual activity*

Saturday, September 20, 2025
Register today!

NON-PROFIT ORG.
U.S. POSTAGE
PAID
UNIVERSITY OF CALIFORNIA,
LOS ANGELES